View press release distributed by EIN Press Access:
https://www.einpresswire.com/article/798651337/biomed-industries-ceo-to-chair-neurosciences-2025-and-present-breakthrough-research-on-alzheimer-s-disease-and-obesity?n=2San Jose, CA — March 31, 2025 — >— Biomed Industries, Inc. (Biomed) announced today that its CEO, Dr. Lloyd Tran will serve as the Conference Chair at the Global Summit on Neuroscience and Neurological Disorders (NeuroSciences 2025) taking place on April 7 – 8 in Valencia, Spain.
As a recognized leader in neuropharmaceutical research, Dr. Tran will also deliver three keynote presentations showcasing Biomed’s latest advancements in neuroscience:
1.Associations Between Alzheimer’s Disease and Obesity: Clinical Trials of NA-831 for AD and NA-931 for Obesity
2. Phase 2 Clinical Trials of NA-831 and NA-901 for the Treatment of Alzheimer’s Disease and Major Depressive Disorder: Supporting the Neurogenesis Hypothesis
3. Associations Between Alzheimer’s Disease and Rett Syndrome: Clinical Trials of NA-831 for AD and NA-921 for the Treatment of Rett Syndrome
The Neuroscience 2025 Summit will bring together leading neuroscientists, clinicians, and industry experts to present and share innovative solutions and breakthroughs to address challenging treatment problems. The Conference aims to provide a forum to stimulate ideas and establish collaborations that can contribute to progress in these critical fields.
“I am honored to serve as the chairman of this important conference” said Dr. Tran. He continued, “Bringing together leading neuroscience researchers from around the world provides a rare opportunity for information exchange and exploration. Biomed has pioneered breakthrough research in the areas of Alzheimer’s Disease, Obesity, and Rett Syndrome, uncovering previously unknown relationships between and among those diseases and conditions. We believe that this research will soon provide viable treatments and offer hope for patients, globally.”
ABOUT BIOMED INDUSTRIES:
Biomed Industries, Inc. is a pioneering biopharmaceutical company dedicated to developing and commercializing novel drug therapeutics to address unmet medical needs. Its research portfolio spans a wide range of conditions, including Alzheimer’s disease, Major Depressive Disorder (MDD), diabetes, obesity, metabolic dysfunction-associated steatohepatitis (MASH), stroke, Alcohol Use Disorder, and rare diseases including Rett Syndrome, Friedreich’s Ataxia and others.
For further information, please visit Biomed Industries' official website: https://www.biomedind.com
CONTACT
Michael WillisFor more news, please visit our News page.
For further information about Biomed Industries, Inc., please contact us.